742352
Last Update Posted: 2008-09-09
Recruiting status is unknown
All Genders accepted | 65 Years + |
40 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.
Eligibility
Relevant conditions:
Atherosclerosis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Einat Even Sapir, MD PhD
evensap@tasmc.health.gov.il
972-3-6973532
Data sourced from ClinicalTrials.gov